JP2023529882A - 細胞内ｍＲＮＡ送達のためのｐＨ応答性リピドイドナノ粒子 - Google Patents

細胞内ｍＲＮＡ送達のためのｐＨ応答性リピドイドナノ粒子 Download PDF

Info

Publication number
JP2023529882A
JP2023529882A JP2022575723A JP2022575723A JP2023529882A JP 2023529882 A JP2023529882 A JP 2023529882A JP 2022575723 A JP2022575723 A JP 2022575723A JP 2022575723 A JP2022575723 A JP 2022575723A JP 2023529882 A JP2023529882 A JP 2023529882A
Authority
JP
Japan
Prior art keywords
compound
lipidoid
o16cba
compound according
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022575723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529882A5 (enExample
Inventor
シュィ，チアオビン
リー，ヤーミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts University
Original Assignee
Tufts University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts University filed Critical Tufts University
Publication of JP2023529882A publication Critical patent/JP2023529882A/ja
Publication of JP2023529882A5 publication Critical patent/JP2023529882A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022575723A 2020-06-12 2021-06-10 細胞内ｍＲＮＡ送達のためのｐＨ応答性リピドイドナノ粒子 Pending JP2023529882A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038451P 2020-06-12 2020-06-12
US63/038,451 2020-06-12
PCT/US2021/036819 WO2021252769A1 (en) 2020-06-12 2021-06-10 Ph-responsive lipidoid nanoparticles for intracellular mrna delivery

Publications (2)

Publication Number Publication Date
JP2023529882A true JP2023529882A (ja) 2023-07-12
JP2023529882A5 JP2023529882A5 (enExample) 2024-06-13

Family

ID=78845924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022575723A Pending JP2023529882A (ja) 2020-06-12 2021-06-10 細胞内ｍＲＮＡ送達のためのｐＨ応答性リピドイドナノ粒子

Country Status (5)

Country Link
US (1) US20230321036A1 (enExample)
EP (1) EP4164647A4 (enExample)
JP (1) JP2023529882A (enExample)
CN (1) CN116018142A (enExample)
WO (1) WO2021252769A1 (enExample)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028487A1 (en) * 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
JP2016510729A (ja) * 2013-02-28 2016-04-11 タフツ ユニバーシティー 薬剤のデリバリーのためのジスルフィド化合物
WO2018140220A1 (en) * 2017-01-27 2018-08-02 Trustees Of Tufts College Nanocomplexes of polyanion-modified proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186366A1 (en) * 2013-05-13 2014-11-20 Tufts University Nanocomplexes for delivery of saporin
US10188606B2 (en) * 2016-10-07 2019-01-29 Mayo Foundation For Medical Education And Research Expansile crosslinked polymersome for pH-sensitive delivery of anticancer drugs
IL276322B2 (en) * 2018-02-01 2024-12-01 Tufts College Lipid-like nanocomplexes and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028487A1 (en) * 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
JP2016510729A (ja) * 2013-02-28 2016-04-11 タフツ ユニバーシティー 薬剤のデリバリーのためのジスルフィド化合物
WO2018140220A1 (en) * 2017-01-27 2018-08-02 Trustees Of Tufts College Nanocomplexes of polyanion-modified proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI, YAMIN ET AL.: "Combinatorial Library of Cyclic Benzylidene Acetal-Containing pH-Responsive Lipidoid Nanoparticles f", BIOCONJUGATE CHEMISTRY, vol. 31 (7), JPN6025029591, 10 June 2020 (2020-06-10), pages 1835 - 1843, ISSN: 0005777466 *

Also Published As

Publication number Publication date
US20230321036A1 (en) 2023-10-12
EP4164647A4 (en) 2024-07-24
WO2021252769A1 (en) 2021-12-16
EP4164647A1 (en) 2023-04-19
CN116018142A (zh) 2023-04-25

Similar Documents

Publication Publication Date Title
CA2980721C (en) Nucleic acid-containing lipid nanoparticles
JP6305344B2 (ja) 活性作用物質の送達のための生分解性脂質
CN112262122A (zh) 化合物或其盐及脂质颗粒
EP3662913A1 (en) Nucleic-acid-containing lipid nanoparticles
JP2022025076A (ja) 脂質粒子を含むキット、脂質粒子を利用した活性剤送達方法、および細胞の作製方法
CN114728016A (zh) 脂质组合物
CN109503411B (zh) 叔胺类阳离子脂质衍生物及其在rna药物递送系统的应用
CN106008272A (zh) 阳离子性脂质
KR20230005367A (ko) 뇌 전달을 위한 합성 지질-유사 물질
JP6887020B2 (ja) 生分解性化合物、脂質粒子、脂質粒子を含む組成物、およびキット
CN120757505A (zh) 一种二烃基咪唑仿生型脂质化合物及其制备方法和应用
CN117843603A (zh) 一种可电离脂质材料及其在制备核酸递送载体中的应用
AU2021425941A1 (en) Unsaturated dendrimers compositions,related formulations, and methods of use thereof
CN1867580B (zh) 被甘油衍生物修饰的化合物
EP2640422B1 (en) Polymeric conjugates of active principles, their process of preparation and their polymeric intermediates
WO2025153095A1 (zh) 一种脂质组合物及其制备方法和应用
CN102936338B (zh) 一种阳离子类脂质体及其制备方法
EP1069107B1 (en) Fullerene derivatives
Oumzil et al. Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating
WO2026002273A1 (zh) 含氮链状化合物、制备方法、包含其的组合物和应用
CN113214171B (zh) 两亲性树形分子、合成及其作为药物递送系统的应用
US20230321036A1 (en) Ph-responsive lipidoid nanoparticles for intracellular mrna delivery
EP4613738A1 (en) Lipid having amide and ester functional groups, and method for producing same
CN114751835B (zh) 一类含有多个酯键可电离叔胺脂质及其合成方法和应用
CN115093434A (zh) 一种藤黄酸纳米制剂及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260121